Literature DB >> 26800664

Association of cytokine gene polymorphisms (IL‑6, IL‑12B, IL‑18) with Behcet's disease : A meta-analysis.

Y Xu1, K Zhou2, Z Yang1, F Li1, Z Wang1, F Xu1, C He3.   

Abstract

PURPOSE: This study aims to investigate the association of cytokine gene polymorphisms with the risk of Behcet's disease (BD) via comprehensive meta-analysis.
METHODS: The Embase and PubMed databases covering the period from the earliest possible year to May 2015 were searched. A total of 13 eligible articles including 2,065 BD patients and 1,559 controls were recruited. Odds ratios (ORs) and 95 % confidence intervals (CIs) were used to assess the strength of the associations. Potential publication bias was evaluated using Egger's linear regression test.
RESULTS: Meta-analysis indicated associations between IL‑6 rs1800795, IL‑12B rs3212227, and IL‑18 rs1946518 in all study subjects: IL‑18 rs1946518 in the dominant model (IL‑18 rs1946518: OR = 0.48, 95 % CI: 0.34-0.70, P = 0.000) and the homozygote model (IL‑18 rs1946518: OR = 0.40, 95 % CI: 0.25-0.65, P = 0.000); and IL‑6 rs1800795 and IL‑12B rs3212227 in the dominant model (IL‑6 rs1800795: OR = 0.53, 95 % CI: 0.39-0.72, P = 0.000; IL‑12B rs3212227: OR = 1.26, 95 % CI: 1.06-1.48, P = 0.007; IL‑18 rs1946518: OR = 0.46, 95 % CI: 0.33-0.65, P = 0.000). No significant evidence for associations of IL‑18 rs187238 polymorphisms with BD susceptibility was detected.
CONCLUSION: In summary, this meta-analysis finds that IL‑6 rs1800795 and IL‑18 rs1946518 polymorphisms decrease the risk of BD. However, IL‑12B rs3212227 increases BD susceptibility. Further large-scale investigation of this association is necessary.

Entities:  

Keywords:  Alleles; Etiology; Homozygote; T-cells; Vasculitis

Mesh:

Substances:

Year:  2016        PMID: 26800664     DOI: 10.1007/s00393-015-0036-4

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  28 in total

1.  IL-18 promoter polymorphisms confer susceptibility to Behçet's disease, particularly to the mucocutaneous form, in a Turkish population.

Authors:  F Keskin; S Pay; U Musabak; R I Sagkan; H Erdem; I Simsek; O Kose; A Dinc; A Sengul
Journal:  Clin Exp Rheumatol       Date:  2009 Mar-Apr       Impact factor: 4.473

2.  Proinflammatory cytokine gene polymorphisms in Behçet's disease.

Authors:  Aliakbar Amirzargar; Farhad Shahram; Enayat Nikoopour; Nima Rezaei; Keyvan Saeedfar; Naghmeh Ziaei; Fereydoun Davatchi
Journal:  Eur Cytokine Netw       Date:  2010-11-09       Impact factor: 2.737

3.  Association of interleukin-2, interleukin-4 and transforming growth factor-beta gene polymorphisms with Behcet's disease.

Authors:  Farhad Shahram; Enayat Nikoopour; Nima Rezaei; Kayvan Saeedfar; Naghmeh Ziaei; Fereydoun Davatchi; Aliakbar Amirzargar
Journal:  Clin Exp Rheumatol       Date:  2011-09-27       Impact factor: 4.473

Review 4.  Systemic lupus erythematosus with Sjögren syndrome compared to systemic lupus erythematosus alone: a meta-analysis.

Authors:  Qingping Yao; Roy D Altman; Xiaofeng Wang
Journal:  J Clin Rheumatol       Date:  2012-01       Impact factor: 3.517

5.  IL18 polymorphism is associated with Behçet's disease but not lupus in patients from Turkey.

Authors:  Jasmine Htoon; Ajay Nadig; Travis Hughes; Sule Yavuz; Haner Direskeneli; Güher Saruhan-Direskeneli; Amr H Sawalha
Journal:  J Rheumatol       Date:  2011-05       Impact factor: 4.666

6.  Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behçet's disease.

Authors:  M Ben Ahmed; H Houman; M Miled; K Dellagi; H Louzir
Journal:  Arthritis Rheum       Date:  2004-07

7.  [Production of Th1/Th2 cytokines and nitric oxide in Behçet's uveitis and idiopathic uveitis].

Authors:  H Guenane; D Hartani; L Chachoua; O S Lahlou-Boukoffa; F Mazari; C Touil-Boukoffa
Journal:  J Fr Ophtalmol       Date:  2006-02       Impact factor: 0.818

8.  Cytokine gene polymorphisms in Behçet's disease and their association with clinical and laboratory findings.

Authors:  K Dilek; A A Ozçimen; H Saricaoğlu; D Saba; A Yücel; M Yurtkuran; M Yurtkuran; H B Oral
Journal:  Clin Exp Rheumatol       Date:  2009 Mar-Apr       Impact factor: 4.473

9.  Polymorphisms of interleukin 6 and interleukin 10 in Egyptian people with Behcet's disease.

Authors:  Roba M Talaat; Mohamed E Ashour; Iman H Bassyouni; Ahmed A Raouf
Journal:  Immunobiology       Date:  2014-03-20       Impact factor: 3.144

10.  Expression of Th-17 and RORγt mRNA in Behçet's Disease.

Authors:  Kamel Hamzaoui; Eya Bouali; Imed Ghorbel; Monia Khanfir; Habib Houman; Agnes Hamzaoui
Journal:  Med Sci Monit       Date:  2011-04
View more
  5 in total

Review 1.  Interleukin-18 in Health and Disease.

Authors:  Koubun Yasuda; Kenji Nakanishi; Hiroko Tsutsui
Journal:  Int J Mol Sci       Date:  2019-02-02       Impact factor: 5.923

2.  CD83+ CCR7+ NK cells induced by interleukin 18 by dendritic cells promote experimental autoimmune uveitis.

Authors:  Qiang Fu; Xuejing Man; Xin Wang; Nannan Song; Yuanbin Li; Jiangnan Xue; Yufei Sun; Wei Lin
Journal:  J Cell Mol Med       Date:  2018-12-08       Impact factor: 5.310

Review 3.  Global Meta-Analysis on the Association between Behcet Syndrome and Polymorphisms from the HLA Class I (A, B, and C) and Class II (DRB1, DQB1, and DPB1) Genes.

Authors:  Cristina Capittini; Chiara Rebuffi; Marco Vincenzo Lenti; Antonio Di Sabatino; Carmine Tinelli; Miryam Martinetti; Annalisa De Silvestri
Journal:  Dis Markers       Date:  2021-12-13       Impact factor: 3.434

4.  Association between interleukin 12B and interleukin 23R gene polymorphisms and systemic lupus erythematosus: a meta-analysis.

Authors:  Jae Hyun Jung; Ji Hyun Lim; Gwan Gyu Song; Bo Young Kim
Journal:  J Int Med Res       Date:  2022-01       Impact factor: 1.671

5.  Exploring the association of IL-10 polymorphisms in Behcet's disease: a systematic review and meta-analysis.

Authors:  Elham Shahriyari; Leila Vahedi; Nasrin Roshanipour; Mohammad Asghari Jafarabadi; Amin Khamaneh; Maryam Ghaffari Laleh
Journal:  J Inflamm (Lond)       Date:  2019-12-23       Impact factor: 4.981

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.